2 ASX healthcare small-cap shares to buy now: brokers

These 2 small-cap healthcare companies have captured the attention of experts.

| More on:
Two lab workers fist pump each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

ASX healthcare shares were in the red yesterday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) down 0.21% while the broader S&P/ASX All Ordinaries Index (ASX: XAO) was up 0.18%.

Here are two ASX healthcare small-cap shares that brokers are backing for future growth.

Experts rate 2 ASX healthcare small-cap shares

Let's see what these brokers have to say.

PYC Therapeutics Ltd (ASX: PYC)

PYC is a clinical-stage ASX biotech in the gene therapy space.

This ASX healthcare small-cap share was trading at $1.74, up 2.96% at the market close on Thursday. PYC shares have risen by an astonishing 1,640% in the year to date.

Canaccord Genuity has a buy rating on PYC Therapeutics shares with a 12-month price target of $2.40. This implies a potential 38% upside for investors.

In a recent note, Canaccord discussed PYC's update to its existing VP-001 Phase I/II dataset for Retinitis Pigmentosa 11, or RP-11. This rare disease causes blindness and has no currently available treatments.

Canaccord analysts Elyse Shapiro and Madeleine Williams said the data update was "broadly positive".

The analysts said:

Net-net, we view the consistency in benefit across LLVA (low luminance visual acuity), and reduced number of scotomas (blind spots) as a positive sign that VP-001 is having a positive impact on functional outcomes.

Patient numbers are low to attribute statistical significance, and the study wasn't powered for this, but the error bars indicate that the data has demonstrated a statistically significant improvement at some, and is extremely close, at certain timepoints, which is very impressive to us.

Shapiro and Williams said there were known immunogenic issues associated with gene therapy for the retina. However, they have confidence in VP-001's safety profile.

We continue to look forward to additional data updates for the high dose segment (75 mcg), and longer-term outcomes from the extension study.

PYC Therapeutics shares were among 8 ASX All Ords stocks upgraded to strong buy ratings last month by analysts on the CommSec trading platform.

4DMedical Ltd (ASX: 4DX)

This company is a medical technology company in the field of lung imaging and ventilation analysis.

This ASX healthcare small-cap share closed at 52 cents, down 5.50% on Thursday and down 28.4% in 2024.

The latest note on 4DMedical from Ord Minnett, published on asx.com.au last week, shows the broker has a speculative buy rating with a share price target of $1.10.

This implies a potential 111.5% upside for investors.

4DMedical presented ongoing clinical trial results of its ventilation and perfusion technology, CT:VQ, at the Radiological Society of North America Annual Meeting in Chicago yesterday.

CT:VQ is an advanced imaging solution that provides an alternative to traditional Nuclear VQ scans, which require the use of radioactive isotopes and other expensive infrastructure.

4DMedical hopes to submit CT:VQ for approval with the US Food and Drug Administration in mid-2025.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »